Navigation Links
Targeted Radiation Therapy Safe, Effective Treatment for Elderly with Pancreatic Cancer
Date:9/24/2013

Detroit, Michigan (PRWEB) September 25, 2013

A highly targeted cancer radiation therapy may offer a safe and effective treatment option for elderly pancreatic cancer patients unable to undergo surgery or combined chemotherapy and radiation therapy, according to researchers at Henry Ford Hospital in Detroit.

Called stereotactic body radiotherapy (SBRT), the study finds patients lived, on average, six to seven months longer following treatment with minimal side-effects even when they had other severe comorbidities such as chronic obstructive pulmonary disease (COPD), heart disease and diabetes.

Two of the patients in the study lived nearly two years.

“Elderly individuals, those ages 75 and older, account for approximately 40 percent of patients diagnosed with pancreatic cancer,” says study lead author Raphael Yechieli, M.D., with the Department of Radiation Oncology at Henry Ford Hospital.

“These patients are too ill to receive any other treatment, but with stereotactic body radiotherapy we’re able to deliver a safe and effective treatment in two weeks that can provide them with a substantial quality of life with minimal side effects.”

The study was presented at the 55nd annual American Society for Radiation Oncology (ASTRO) meeting in Atlanta.

In 2013, there will be an estimated 45,220 new cases of pancreatic cancer, and approximately 38,460 will die from the disease, according to the National Cancer Institute. Risk factors for pancreatic cancer include smoking, diabetes, obesity, family history of the disease and pancreatitis. Most people diagnosed with the disease are older than 65.

Surgery is the only known cure for resectable pancreatic cancer, where the cancer is localized to the pancreas and hasn't spread. It is estimated that only 20 percent of pancreatic cancer patients have their tumors present with localized disease amendable to surgical removal.

A select number of those patients, however, are not candidates for surgery due to having other co-morbidities such as COPD, heart disease and diabetes. This leaves only chemotherapy and radiation, or a combination of the two, available for treatment.

But for a large portion of elderly patients with localized pancreatic cancer even chemotherapy and radiation therapy are not options.

The Henry Ford study looked to determine if SBRT – a method of giving radiation that can be highly targeted to the tumor, sparing the normal tissue around it – was a viable option for this group of patients. SBRT provides a higher dose of radiation, meaning patients have fewer treatments. In this case, treatment averaged two weeks.

The study included 20 patients with a median age of 83, all of whom were medically unable to tolerate surgery or combined chemo-radiation therapy. The majority of patients in the study (90 percent) received SBRT treatment at the time of diagnosis.

Seven patients reported side-effects from treatment: nausea, vomiting and fatigue.

Among the patients: 13 had a recurrence of cancer; nine had cancer spread from the original tumor to distant organs or distant lymph nodes.

Median overall survival was 6.7 months, and median recurrence-free survival was 8.1 months. At six months post-treatment, 61 percent of patients were alive; two patients in the study survived nearly two years.

“National trends tell us that very few patients over the age of 75 are getting any treatment at all for pancreatic cancer due to comorbidity risks,” notes Dr. Yechieli. “So we want to push the envelope to give them a treatment option that, while not a cure, is short, effective and safe, and has the potential to give them a good quality of life.”

The next step in this research, Dr. Yechieli says, is to closely follow patients after SBRT and get their direct feedback to measure post-treatment quality of life.

Along with Dr. Yechieli, Henry Ford study co-authors are Jared Rex Robbins, M.D.; Meredith Mahan; Farzan Siddiqui, M.D., Ph.D.; Munther Ajlouni, M.D.

Research funding: Henry Ford Hospital

Read the full story at http://www.prweb.com/releases/2013/9/prweb11155793.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Targeted radiation therapy safe, effective treatment for elderly with pancreatic cancer
2. Michigan-Based Stryker Corp. and Its Howmedica Osteonics Subsidiary Are Targeted in Defective Hip Implant Lawsuit
3. Targeted Medical Pharma Initiates Clinical Trial of Red Blood Cell Stimulating Formulation
4. ProEPA™ with Concentrated GLA from Nordic Naturals Offers High Concentrations of EPA and GLA for Targeted Support
5. Shape of nanoparticles points the way toward more targeted drugs
6. MGH-led studies shed new light on targeted lung cancer therapy
7. Many solid tumors carry genetic changes targeted by existing compounds
8. Researchers provide rationale for use of targeted immunotherapy in sarcomatoid lung carcinomas
9. Research finds targeted screening for hepatitis C is cost-effective
10. Targeted toxin active in platinum-resistant ovarian cancers
11. The future of personalized and targeted cancer therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... ... provost of Liberty University, has officially announced the appointment of Peter A. Bell, ... College of Osteopathic Medicine (LUCOM), beginning April 10. Dr. Bell comes to ...
(Date:2/24/2017)... ... , ... The narrative in “ Signal 8: An Australian Paramedic’s Story ” ... paramedic experiences. Schanssema describes the tragedies he saw, as well as his struggles with ... Schanssema, initially unsure of the career path he wanted to take, found fulfillment in ...
(Date:2/24/2017)... ... ... Indiana Fiber Network (IFN) President and CEO Kelly C. Dyer recently announced ... the Chairman of the Management Committee when IFN was originally formed in 2002 where ... investor/owners and development of the business plan. He became the first paid employee ...
(Date:2/23/2017)... ... 23, 2017 , ... Thinksport, the most award-winning sunscreen on ... of Marin. For the second year in a row, cyclists will stay protected ... are thrilled to provide our safe, non-toxic sunscreen to over 2,000 cycling enthusiasts ...
(Date:2/23/2017)... Chapel Hill, NC (PRWEB) , ... February 23, 2017 , ... ... the Platinum Sponsor for ACPA’s 74th Annual Meeting. KLS is a longtime supporter ... in 2017 as an exhibitor and Platinum Sponsor," said Dr. Bob Havlik, 2017 ACPA ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... Following receiving ... , s AMAR is a major milestone for the ... M w ound care market in ... BST for inclusion in the National Health Basket , ...   E-QURE Corp. (OTCQB: EQUR), a leader in medical devices ...
(Date:2/24/2017)... Feb 24, 2017 Research and Markets has announced ... 2016" report to their offering. ... The latest research Hemophilia Drugs Price Analysis and Strategies - ... The research answers the following questions: ... How are they positioned in the Global Hemophilia market? ...
(Date:2/24/2017)... Feb. 24, 2017 Medical information groups ... increase their self-service capabilities to manage inquiries from ... New research from consulting leader Best ... developed self-service website portals where HCPs can sign ... one of many findings to emerge from the ...
Breaking Medicine Technology: